Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 0.77 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.77 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.77 |
| ▸ | TNF | P01375 | 11/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851127 | 0.94 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4856274 | 0.91 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4848127 | 0.88 | PDE4B (0.77) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6098481 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL3120500 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL537314 | 0.86 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6098976 | 0.86 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL7746632 | 0.84 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4847642 | 0.84 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL21215174 | 0.84 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE CORPORATION | 2008-11-13 | — | — | US | claimed |
| US-7345062-B2 | Substituted acylhydroxamic acids and method of reducing TNFαlevels | CELGENE CORPORATION (US) | 2008-03-18 | — | — | US | claimed |
| US-6699899-B1 | ISOINDOLE DERIVATIVES; ANTIINFLAMMATORY, ANTIPYRETIC, AND ANTICOAGULANT AGENTS | CELGENE CORPORATION | 2004-03-02 | — | — | US | claimed |
| WO-2017070291-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-3142663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-3065778-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9408831-B2 | Methods for treating respiratory viral infection | CELGENE CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2015175956-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015069711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20130136770-A1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | CELGENE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2583098-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORPORATION (US) | 2013-04-24 | — | — | EP | disclosed |
| WO-2004043378-A2 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004037207-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-6699899-B1 | ISOINDOLE DERIVATIVES; ANTIINFLAMMATORY, ANTIPYRETIC, AND ANTICOAGULANT AGENTS | CELGENE CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-6699899-B1 | ISOINDOLE DERIVATIVES; ANTIINFLAMMATORY, ANTIPYRETIC, AND ANTICOAGULANT AGENTS | CELGENE CORPORATION | 2004-03-02 | — | — | US | disclosed |
| EP-1246620-A4 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-G(A) LEVELS | CELGENE CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| CN-1413109-A | Substituted acylhydroxamic acids and methods for reducing TNF-alpha levels | CELGENE CORP (US) | 2003-04-23 | — | — | CN | disclosed |
| EP-1246620-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-G(A) LEVELS | CELGENE CORPORATION (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001045702-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136770-A1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | PDE4A, PDE4B, IL4 | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | APEH, TNF, ACOX3 | PDE4A 30/4885PDE4B 70/4885PDE4C 53/4885 |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | IL6, IL2, IL6ST | PDE4A 498/4885PDE4B 561/4885PDE4C 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.